{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:44:29Z","timestamp":1788911069470,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2019RU022"],"award-info":[{"award-number":["2019RU022"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81991491"],"award-info":[{"award-number":["81991491"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072323"],"award-info":[{"award-number":["82072323"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273640"],"award-info":[{"award-number":["82273640"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["20720200105"],"award-info":[{"award-number":["20720200105"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["20720220006"],"award-info":[{"award-number":["20720220006"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Science Bulletin"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.scib.2023.09.020","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T13:28:39Z","timestamp":1695130119000},"page":"2448-2455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6\/11\/16\/18\/31\/33\/45\/52\/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial"],"prefix":"10.1016","volume":"68","author":[{"given":"Yue-Mei","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Feng","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Zhu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Li","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Wen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kong-Xin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Hui","family":"Wang-Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Min","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Xing","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Fen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ying","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou-Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Shao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.scib.2023.09.020_b0005","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis","volume":"8","author":"de Martel","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.scib.2023.09.020_b0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens\u2014Part B: biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.scib.2023.09.020_b0015","unstructured":"ICO\/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in the world. 2023, https:\/\/hpvcentre.net\/statistics\/reports\/XWX.pdf?t=1693896342213."},{"key":"10.1016\/j.scib.2023.09.020_b0020","unstructured":"ICO\/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in China. 2023, https:\/\/hpvcentre.net\/statistics\/reports\/CHN.pdf?t=1693896412698."},{"key":"10.1016\/j.scib.2023.09.020_b0025","doi-asserted-by":"crossref","unstructured":"Lacey CJN, Guimera N, Garland SM. Chapter 10 - Low-risk human papillomavirus: Genital warts, cancer and respiratory papillomatosis. In: Jenkins D, Bosch F X, editors. Human papillomavirus. Massachusetts: Academic Press. 2020. 165\u2013178.","DOI":"10.1016\/B978-0-12-814457-2.00010-6"},{"key":"10.1016\/j.scib.2023.09.020_b0030","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S1470-2045(22)00567-8","article-title":"HPV vaccination in South Asia: new progress, old challenges","volume":"23","author":"The","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.scib.2023.09.020_b0035","unstructured":"World Health Organization. Human papillomavirus vaccines: WHO position paper, December 2022. 2022, https:\/\/www.who.int\/publications\/i\/item\/who-wer9750-645-672."},{"key":"10.1016\/j.scib.2023.09.020_b0040","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/ijgc-2020-001285","article-title":"World Health Organization call for action to eliminate cervical cancer globally","volume":"30","author":"Gultekin","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.scib.2023.09.020_b0045","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S1473-3099(22)00435-2","article-title":"Efficacy, safety, and immunogenicity of an Escherichia coli-produced human papillomavirus (16 and 18) l1 virus-like-particle vaccine: End-of-study analysis of a phase 3, double-blind, randomised, controlled trial","volume":"22","author":"Zhao","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.scib.2023.09.020_b0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41541-017-0006-8","article-title":"Escherichia coli-derived virus-like particles in vaccine development","volume":"2","author":"Huang","year":"2017","journal-title":"npj Vaccines"},{"key":"10.1016\/j.scib.2023.09.020_b0055","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S1470-2045(14)71179-9","article-title":"Next generation prophylactic human papillomavirus vaccines","volume":"16","author":"Schiller","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.scib.2023.09.020_b0060","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jnci\/djz074","article-title":"Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial","volume":"112","author":"Qiao","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.scib.2023.09.020_b0065","article-title":"Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus l1 virus-like particle vaccine (types 6\/11\/16\/18\/31\/33\/45\/52\/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial","volume":"34","author":"Chu","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.scib.2023.09.020_b0070","doi-asserted-by":"crossref","unstructured":"Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine, 2006, 24 Suppl 3: S3\/106\u2013113.","DOI":"10.1016\/j.vaccine.2006.05.110"},{"key":"10.1016\/j.scib.2023.09.020_b0075","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.vaccine.2017.12.042","article-title":"Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals","volume":"36","author":"Widdice","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.scib.2023.09.020_b0080","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1097\/INF.0b013e318206c26e","article-title":"Immunogenicity and safety of human papillomavirus-16\/18 as04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study","volume":"30","author":"Esposito","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.scib.2023.09.020_b0085","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/21645515.2020.1761202","article-title":"Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals","volume":"16","author":"Yu","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.scib.2023.09.020_b0090","doi-asserted-by":"crossref","first-page":"6096","DOI":"10.1016\/j.vaccine.2020.07.030","article-title":"Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages","volume":"38","author":"Chen","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.scib.2023.09.020_b0095","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.it.2022.07.011","article-title":"Single-dose HPV vaccine immunity: is there a role for non-neutralizing antibodies?","volume":"43","author":"Quang","year":"2022","journal-title":"Trends Immunol"},{"key":"10.1016\/j.scib.2023.09.020_b0100","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(21)00453-8","article-title":"Vaccine efficacy against persistent human papillomavirus (HPV) 16\/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study","volume":"22","author":"Basu","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.scib.2023.09.020_b0105","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100056","article-title":"Efficacy of single-dose HPV vaccination among young African women","volume":"1","author":"Barnabas","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.scib.2023.09.020_b0110","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/jnci\/djaa010","article-title":"Durability of cross-protection by different schedules of the bivalent HPV vaccine: the CVT trial","volume":"112","author":"Tsang","year":"2020","journal-title":"J Natl Cancer Inst"}],"container-title":["Science Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927323006369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927323006369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:58:00Z","timestamp":1761868680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095927323006369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":22,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2095927323006369"],"URL":"https:\/\/doi.org\/10.1016\/j.scib.2023.09.020","relation":{},"ISSN":["2095-9273"],"issn-type":[{"value":"2095-9273","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6\/11\/16\/18\/31\/33\/45\/52\/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial","name":"articletitle","label":"Article Title"},{"value":"Science Bulletin","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.scib.2023.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Science China Press. Published by Elsevier B.V. and Science China Press.","name":"copyright","label":"Copyright"}]}}